International Journal of Molecular and Cellular Medicine (IJMCM)
Cellular and Molecular Biology Research Center, Babol University of Medical Sciences
Fri, Mar 14, 2025
[Archive]
Volume 0 - Int J Mol Cell Med (In Progress)
Int J Mol Cell Med 2025, 0 - Int J Mol Cell Med (In Progress): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Anbari K, Ghanadi K. Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment. Int J Mol Cell Med 2025;
URL: http://ijmcmed.org/article-1-2369-en.html
URL: http://ijmcmed.org/article-1-2369-en.html
1- Social Determinants of Health Research Center, Lorestan University of Medical Science, Khorramabad, Iran.
2- Internal Department, School of Medicine, Lorestan University of Medical Science, Khorramabad, Iran. ,Koroush.ghanadi@gmail.com
2- Internal Department, School of Medicine, Lorestan University of Medical Science, Khorramabad, Iran. ,
Abstract: (318 Views)
By 2040 the burden of colorectal cancer will increase to 3.2 million new cases per year and 1.6 million deaths per year. This highlights the importance of improving preventive measures and treatment strategies. This piece concisely overviews the latest therapeutic and diagnostic approaches for colorectal cancer. In 2019, factors such as low milk intake, smoking, insufficient calcium consumption, and alcohol use had a significant impact on colorectal cancer DALYs worldwide. A comprehensive search was conducted in December 2023 using keywords related to drugs, therapeutic agents, colorectal cancer, diagnostic methods, epidemiology, and novel therapeutic approaches in the PubMed and Scopus databases. Initially, 325 articles were identified based on titles, abstracts, and publication dates. After removing duplicates, 170 unique articles were included. Medications like Nimotuzumab, Cetuximab, and Panitumumab target the Epidermal Growth Factor Receptor (EGFR), which EGF activates. HER2, activated by ligands, is the focus of drugs like Trastuzumab and Pertuzumab. The PD-1/PD-L1 and CTLA-4 pathways, as the immune checkpoints, which involve T cells, are targeted by medications like Ipilimumab. Adoptive cell therapy, including CAR-T cell therapy, TCR modification, and enhancing T cell activity through tumor-infiltrating lymphocytes, is used to combat cancer cell growth. In medical advancements, adoptive cell transfer therapy (ACT) and exosomes in the tumor immune microenvironment (TME) are notable treatment methods that boost the immune system. HIF1A-AS1, CRNDE-h, NEAT1, ZFAS1, and GAS5, along with IGFBP-2, have demonstrated significant CRC diagnostic capacity. Compared to CRC patients with low HIF1A-AS1 expression, individuals with high expression levels were linked to a worse 5-year survival rate.
Type of Study: Review |
Subject:
Cancer
Received: 2024/07/6 | Accepted: 2024/07/23 | Published: 2025/01/7
Received: 2024/07/6 | Accepted: 2024/07/23 | Published: 2025/01/7
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
